Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

Rhea-AI Summary

On April 4, 2023, Novavax, Inc. (Nasdaq: NVAX) announced its participation in the World Vaccine Congress (WVC) and the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company will showcase data on its COVID-19 prototype vaccine as a booster and its COVID-Influenza Combination (CIC) vaccine. Key presentations include insights on vaccine hesitancy and safety surveillance, scheduled from April 3 to 6 in Washington, DC, and April 15 to 18 in Copenhagen, Denmark. Novavax is also a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards in two categories, with winners announced on April 4.

Positive

• Presentation of COVID-19 prototype vaccine and CIC data could enhance investor confidence.
• Finalist status for Vaccine Industry Excellence Awards may boost public perception and credibility.

Negative

• None.

GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.

At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participate in a panel discussion on The Future of Safety for New Vaccines on April 5. In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4.

At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.

Novavax presentations during WVC: 

Author	Presentation title	Details
Dunkle, L	Novavax COVID-19 Vaccine: Latest Booster Data and Clinical Updates	Oral Presentation April 5, 2023 10:10am (EDT)
Shinde, V	Update on Novavax Influenza and COVID- Influenza Combination Vaccine	Oral Presentation April 5, 2023 3:25pm (EDT)
Fix, J	Safety surveillance for COVID-19 vaccines: challenges in the pandemic and endemic settings	Oral Presentation April 5, 2023 12:10pm (EDT)

Novavax presentations during ECCMID:   

Author	Presentation title	Details
Shinde, V	Immunogenicity of a novel COVID-Influenza Combination (CIC) vaccine assessed with response surface modelling (RSM)	Oral Presentation  Abstract #02042  April 16, 2023  8:30am (CEST)
Toback, S	Interim analysis of an observer- blinded, randomized phase 3 study to evaluate the safety and immunogenicity of a single booster of the NVX-CoV2373 vaccine in adults previously vaccinated with the BBIBP-CorV vaccine	Poster Presentation  Poster #P2698  April 17, 2023  12:00pm (CEST)
Marchese, A	Reported pregnancy outcomes across NVX-CoV2373 COVID-19 vaccine primary series and booster dose clinical studies	Poster Presentation  Poster #P2521  April 17, 2023  12:00pm (CEST)
Marchese, A	Healthcare provider perceptions of current and future uptake of  COVID-19 vaccines in Europe and North America	Poster Presentation  Poster #P2755  April 17, 2023  12:00pm (CEST)
Bennett, C	LATE-BREAKER: Immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M adjuvant (NVX- CoV2373) in well-controlled vs less well-controlled people living with HIV	Poster Presentation  Poster #LB039  April 18, 2023  12:00pm (CEST)

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. 

The World Vaccine Congress
The World Vaccine Congress is a series of conferences and exhibitions that have grown over 23 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.

CONTACTS

Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Ali Chartan
240-720-7804
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-grows-presence-at-world-vaccine-congress-2023-and-33rd-european-congress-of-clinical-microbiology--infectious-diseases-301788683.html

SOURCE Novavax, Inc.

FAQ

What is Novavax presenting at the World Vaccine Congress 2023?

Novavax will present data on its COVID-19 prototype vaccine and the COVID-Influenza Combination (CIC) vaccine.

When is Novavax's presentation scheduled at the WVC?

Presentations are scheduled from April 3 to 6, 2023.

What awards has Novavax been nominated for?

Novavax is a finalist for the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award at the World Vaccine Congress.

When will the winners of the Vaccine Industry Excellence Awards be announced?

Winners will be announced on April 4, 2023.

What data will Novavax present at ECCMID?

Novavax will present data on the CIC vaccine and conduct four poster presentations related to its COVID-19 prototype vaccine.